Listed

InMed Pharmaceuticals Inc.

INMNasdaqCIK 1728328HealthcareFiscal year ends Jun 30

Latest reported revenue, Q2 FY2026$820.2kRevenue, Q2 FY2026, three months to 2025-12-31$820.2k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figureThree months to Dec 31, 2025, from the 10-Q filed Feb 11, 2026.

Latest quarter: Q4 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenuenot reported (Revenue not reported)No year-earlier figure to compare
  • Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
  • Operating marginnot reported (Operating income and Revenue not reported)No year-earlier figure to compare
  • Net marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$820.2kGross margin 22.5%
Diluted EPS−$0.73, Q3 FY2026
InMed Pharmaceuticals Inc., key figures for the last eight quarters
Line itemUnitQ1 FY20252024-09-30Q2 FY20252024-12-31Q3 FY20252025-03-31Q4 FY20252025-06-30Q1 FY20262025-09-30Q2 FY20262025-12-31Q3 FY20262026-03-31Q4 FY20262026-06-30Shape over the periods
Revenue$k1,265Revenue, Q1 FY2025, three months to 2024-09-30$1.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure1,112Revenue, Q2 FY2025, three months to 2024-12-31$1.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure1,262Revenue, Q3 FY2025, three months to 2025-03-31$1.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure1,305Revenue, Q4 FY2025, three months to 2025-06-30$1.3m. XBRL concept us-gaap:Revenues. 10-K filed 2025-09-23, accession 0001213900-25-090210. Derived: 12-month figure less the 9-month figure.Report this figure1,120Revenue, Q1 FY2026, three months to 2025-09-30$1.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure820Revenue, Q2 FY2026, three months to 2025-12-31$820.2k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)
Gross margin%39.0%Gross margin, Q1 FY2025, three months to 2024-09-30. gross profit / revenueGross profit: $493.4k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Revenue: $1.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure41.5%Gross margin, Q2 FY2025, three months to 2024-12-31. gross profit / revenueGross profit: $460.9k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Revenue: $1.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure13.9%Gross margin, Q3 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $175.6k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Revenue: $1.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure44.2%Gross margin, Q4 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $576.7k. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-09-23, accession 0001213900-25-090210. Derived: 12-month figure less the 9-month figure.Revenue: $1.3m. XBRL concept us-gaap:Revenues. 10-K filed 2025-09-23, accession 0001213900-25-090210. Derived: 12-month figure less the 9-month figure.Report this figure36.0%Gross margin, Q1 FY2026, three months to 2025-09-30. gross profit / revenueGross profit: $403.2k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Revenue: $1.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure22.5%Gross margin, Q2 FY2026, three months to 2025-12-31. gross profit / revenueGross profit: $184.2k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Revenue: $820.2k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figurenot reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)
Operating margin%not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income and Revenue not reported)not reported (Operating income and Revenue not reported)
Net margin%(132.7%)Net margin, Q1 FY2025, three months to 2024-09-30. net income / revenueNet income: −$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Revenue: $1.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure(231.6%)Net margin, Q2 FY2025, three months to 2024-12-31. net income / revenueNet income: −$2.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Revenue: $1.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure(168.1%)Net margin, Q3 FY2025, three months to 2025-03-31. net income / revenueNet income: −$2.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Revenue: $1.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-12, accession 0001213900-25-042126.Report this figure(137.1%)Net margin, Q4 FY2025, three months to 2025-06-30. net income / revenueNet income: −$1.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-09-09, accession 0001213900-26-098419. Derived: 12-month figure less the 9-month figure.Revenue: $1.3m. XBRL concept us-gaap:Revenues. 10-K filed 2025-09-23, accession 0001213900-25-090210. Derived: 12-month figure less the 9-month figure.Report this figure(154.2%)Net margin, Q1 FY2026, three months to 2025-09-30. net income / revenueNet income: −$1.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Revenue: $1.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure(247.3%)Net margin, Q2 FY2026, three months to 2025-12-31. net income / revenueNet income: −$2.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Revenue: $820.2k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)
Diluted EPS$ per share(2.71)Diluted EPS, Q1 FY2025, three months to 2024-09-30−$2.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure(3.64)Diluted EPS, Q2 FY2025, three months to 2024-12-31−$3.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure(1.94)Diluted EPS, Q3 FY2025, three months to 2025-03-31−$1.94 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figurenot reported (Diluted EPS not reported)(0.44)Diluted EPS, Q1 FY2026, three months to 2025-09-30−$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001213900-25-107152.Report this figure(0.51)Diluted EPS, Q2 FY2026, three months to 2025-12-31−$0.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-11, accession 0001213900-26-014996.Report this figure(0.73)Diluted EPS, Q3 FY2026, three months to 2026-03-31−$0.73 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-06, accession 0001213900-26-052920.Report this figurenot reported (Diluted EPS not reported)
Free cash flow$knot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$4.9mGross margin 34.5%
Diluted EPS−$3.12, FY2026
Free cash flow−$7.0m, FY2024
InMed Pharmaceuticals Inc., key figures for the last five fiscal years
Line itemUnitFY20222022-06-30FY20232023-06-30FY20242024-06-30FY20252025-06-30FY20262026-06-30Shape over the periods
Revenue$m1.4Revenue, FY2022, twelve months to 2022-06-30$1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2022-09-23, accession 0001213900-22-058355.Report this figure4.1Revenue, FY2023, twelve months to 2023-06-30$4.1m. XBRL concept us-gaap:Revenues. 10-K filed 2024-09-30, accession 0001213900-24-082843.Report this figure4.6Revenue, FY2024, twelve months to 2024-06-30$4.6m. XBRL concept us-gaap:Revenues. 10-K filed 2025-09-23, accession 0001213900-25-090210.Report this figure4.9Revenue, FY2025, twelve months to 2025-06-30$4.9m. XBRL concept us-gaap:Revenues. 10-K filed 2025-09-23, accession 0001213900-25-090210.Report this figurenot reported (Revenue not reported)
Gross margin%39.8%Gross margin, FY2022, twelve months to 2022-06-30. gross profit / revenueGross profit: $543.5k. XBRL concept us-gaap:GrossProfit. 10-K filed 2023-09-29, accession 0001213900-23-080842.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2022-09-23, accession 0001213900-22-058355.Report this figure33.9%Gross margin, FY2023, twelve months to 2023-06-30. gross profit / revenueGross profit: $1.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-09-30, accession 0001213900-24-082843.Revenue: $4.1m. XBRL concept us-gaap:Revenues. 10-K filed 2024-09-30, accession 0001213900-24-082843.Report this figure23.9%Gross margin, FY2024, twelve months to 2024-06-30. gross profit / revenueGross profit: $1.1m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-09-23, accession 0001213900-25-090210.Revenue: $4.6m. XBRL concept us-gaap:Revenues. 10-K filed 2025-09-23, accession 0001213900-25-090210.Report this figure34.5%Gross margin, FY2025, twelve months to 2025-06-30. gross profit / revenueGross profit: $1.7m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-09-23, accession 0001213900-25-090210.Revenue: $4.9m. XBRL concept us-gaap:Revenues. 10-K filed 2025-09-23, accession 0001213900-25-090210.Report this figurenot reported (Gross profit and Revenue not reported)
Operating margin%(1361.9%)Operating margin, FY2022, twelve months to 2022-06-30. operating income / revenueOperating income: −$18.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-09-29, accession 0001213900-23-080842.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2022-09-23, accession 0001213900-22-058355.Report this figure(192.2%)Operating margin, FY2023, twelve months to 2023-06-30. operating income / revenueOperating income: −$7.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-09-29, accession 0001213900-23-080842.Revenue: $4.1m. XBRL concept us-gaap:Revenues. 10-K filed 2024-09-30, accession 0001213900-24-082843.Report this figurenot reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income and Revenue not reported)
Net margin%(1361.9%)Net margin, FY2022, twelve months to 2022-06-30. net income / revenueNet income: −$18.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-09-29, accession 0001213900-23-080842.Revenue: $1.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2022-09-23, accession 0001213900-22-058355.Report this figure(192.2%)Net margin, FY2023, twelve months to 2023-06-30. net income / revenueNet income: −$7.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-09-30, accession 0001213900-24-082843.Revenue: $4.1m. XBRL concept us-gaap:Revenues. 10-K filed 2024-09-30, accession 0001213900-24-082843.Report this figure(166.9%)Net margin, FY2024, twelve months to 2024-06-30. net income / revenueNet income: −$7.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-09-23, accession 0001213900-25-090210.Revenue: $4.6m. XBRL concept us-gaap:Revenues. 10-K filed 2025-09-23, accession 0001213900-25-090210.Report this figure(165.1%)Net margin, FY2025, twelve months to 2025-06-30. net income / revenueNet income: −$8.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-09-09, accession 0001213900-26-098419.Revenue: $4.9m. XBRL concept us-gaap:Revenues. 10-K filed 2025-09-23, accession 0001213900-25-090210.Report this figurenot reported (Revenue not reported)
Diluted EPS$ per share(33.17)Diluted EPS, FY2022, twelve months to 2022-06-30−$33.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-09-29, accession 0001213900-23-080842.Report this figure(3.25)Diluted EPS, FY2023, twelve months to 2023-06-30−$3.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-09-30, accession 0001213900-24-082843.Report this figure(20.14)Diluted EPS, FY2024, twelve months to 2024-06-30−$20.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-09-23, accession 0001213900-25-090210.Report this figure(8.36)Diluted EPS, FY2025, twelve months to 2025-06-30−$8.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-09-09, accession 0001213900-26-098419.Report this figure(3.12)Diluted EPS, FY2026, twelve months to 2026-06-30−$3.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-09-09, accession 0001213900-26-098419.Report this figure
Free cash flow$m(15.6)Free cash flow, FY2022, twelve months to 2022-06-30. operating cash flow − capital expenditureOperating cash flow: −$15.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-09-29, accession 0001213900-23-080842.Capital expenditure: $39.1k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-09-29, accession 0001213900-23-080842.Report this figure(7.4)Free cash flow, FY2023, twelve months to 2023-06-30. operating cash flow − capital expenditureOperating cash flow: −$7.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-09-30, accession 0001213900-24-082843.Capital expenditure: $160.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-09-30, accession 0001213900-24-082843.Report this figure(7.0)Free cash flow, FY2024, twelve months to 2024-06-30. operating cash flow − capital expenditureOperating cash flow: −$7.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-09-23, accession 0001213900-25-090210.Capital expenditure: $9.3k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-09-23, accession 0001213900-25-090210.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

By month, by reported value, last 24 monthsPurchases $5.28Sales $0
InMed Pharmaceuticals Inc., open-market insider transactions
DateInsiderTransactionSharesReported priceValueFiling
2026-10-23ADAR1 Capital Management, LLC10% owner Purchase4$1.32$5.28Form 4

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding InMed Pharmaceuticals Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
ADAR1 Capital Management, LLC2026-06-30$1.2m800,000New+800,000
Vivo Capital, LLC2026-06-30$1.2m798,377New+798,377
Squadron Capital Management LLC2026-06-30$503.8k325,000New+325,000
Ikarian Capital, LLC2026-06-30$379.8k245,025New+245,025
Ursa Fund Management, LLC2026-06-30$195.0k125,800New+125,800
MONTANOVA CAPITAL, LLC2026-06-30$155.0k100,000New+100,000
BOOTHBAY FUND MANAGEMENT, LLC2026-06-30$115.1k74,244New+74,244
SABBY MANAGEMENT, LLC2026-06-30$69.7k44,970Reduced−175,290
JANE STREET GROUP, LLC2026-06-30$66.8k43,078New+43,078
Venrock Adviser, LLC2026-06-30$50.7k32,685New+32,685

Recent filings

All 509 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

InMed Pharmaceuticals Inc., recent filings
FiledFormWhat it isAccession number
2026-09-1817:11 ET8-K3.01 Delisting notice; 8.01 Other events; 9.01 Financial statements and exhibits0001213900-26-101492
2026-09-0916:31 ET10-KAnnual reportPeriod 2026-06-300001213900-26-098419
2026-07-2216:28 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001213900-26-080414
2026-07-1016:02 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-077127
2026-06-1021:32 ETSCHEDULE 13DOwnership report, active investor0001213900-26-067514
2026-06-1006:01 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001062993-26-003132
2026-05-1910:32 ET8-K1.01 Entry into a material agreement; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001213900-26-058795
2026-05-1906:03 ET8-K1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 8.01 Other events; 9.01 Financial statements and exhibits0001062993-26-002787
2026-05-0718:12 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001062993-26-002371
2026-05-0617:25 ET10-QQuarterly reportPeriod 2026-03-310001213900-26-052920

Latest annual report

Form 10-K for the fiscal year ended Jun 30, 2026Filed Sep 9, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1728328
Tickers
INM
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Jun 30
Incorporated in
A1
Filer category
Non-accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 04:34 ET. Listed shows no prices and gives no investment advice.